Abstract | OBJECTIVE: METHODS: This study was based on data gathered from a large postmarketing study on levonorgestrel-releasing intrauterine system users (n = 17,360) carried out in Finland. The results present an incidence comparison between levonorgestrel system user data and the data on average Finnish female population (derived from the Finnish Cancer Registry), between 30 and 54 years of age. RESULTS: Based on the 95% confidence intervals for the incidences of breast cancer, and the Fisher exact test, there is no indication of a difference between the levonorgestrel system users and average Finnish female population in any of the 5-year age groups. The incidence rate per 100,000 woman-years was for the age groups 30-34 years 27.2 and 25.5, for 35-39 years 74.0 and 49.2, for 40-44 years 120.3 and 122.4, for 45-49 years 203.6 and 232.5, and for 50-54 years 258.5 and 272.6, in the levonorgestrel system group and in Finnish female population, respectively. CONCLUSION: The results suggest that the use of the levonorgestrel-releasing intrauterine system is not associated with an increased risk of breast cancer.
|
Authors | Tiina Backman, Ilkka Rauramo, Kimmo Jaakkola, Pirjo Inki, Katja Vaahtera, Aino Launonen, Markku Koskenvuo |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 106
Issue 4
Pg. 813-7
(Oct 2005)
ISSN: 0029-7844 [Print] United States |
PMID | 16199640
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Contraceptive Agents, Female
- Levonorgestrel
|
Topics |
- Adult
- Age Distribution
- Aged
- Breast Neoplasms
(epidemiology)
- Case-Control Studies
- Contraceptive Agents, Female
(administration & dosage)
- Female
- Finland
(epidemiology)
- Humans
- Incidence
- Intrauterine Devices, Medicated
- Levonorgestrel
(administration & dosage)
- Middle Aged
- Product Surveillance, Postmarketing
|